MALAT1 and Hyperglycemia: A study reported that the expression of lncRNA MALAT1 was upregulated in the early stage but subsequently downregulated in the late stage under hyperglycaemia, which in turn regulated glucose-induced oxidative stress and the inflammatory response through activation of serum amyloid antigen 3 (SAA3), an inflammatory ligand and target of MALAT1, thus possibly influencing endothelial stability 50.